This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Albuleukin

GlaxoSmithKline plc

Drug Names(s): Albumin-interleukin-2

Description: Albuleukin is a fusion protein of recombinant human interleukin-2 (rIL-2) and recombinant human serum albumin (rHSA).

Deal Structure: In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.


Albuleukin News

Pink Sheet Trademark Review


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug